# Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

> **NCT04108858** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- HER2-Positive Breast Carcinoma
- Metastatic Breast Carcinoma

## Interventions

- **DRUG:** Copanlisib
- **BIOLOGICAL:** Pertuzumab
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT04108858
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-20
- **Primary completion:** 2022-04-29
- **Final completion:** 2022-04-29
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Inadequate accrual rate
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04108858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04108858, "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04108858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*